Advertisement

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies

  • Tiphaine Cholley
    Affiliations
    Department of Pharmacy, University Hospital, Besançon, France
    Search for articles by this author
  • Antoine Thiery-Vuillemin
    Affiliations
    Department of Medical Oncology, University Hospital, Besançon, France

    INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, University Bourgogne Franche-Comté, Besançon, France
    Search for articles by this author
  • Samuel Limat
    Affiliations
    Department of Pharmacy, University Hospital, Besançon, France

    INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, University Bourgogne Franche-Comté, Besançon, France
    Search for articles by this author
  • Marion Hugues
    Affiliations
    Department of Pharmacy, University Hospital, Besançon, France
    Search for articles by this author
  • Fabien Calcagno
    Affiliations
    Department of Medical Oncology, University Hospital, Besançon, France

    INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, University Bourgogne Franche-Comté, Besançon, France
    Search for articles by this author
  • Guillaume Mouillet
    Affiliations
    Department of Pharmacy, University Hospital, Besançon, France
    Search for articles by this author
  • Amélie Anota
    Affiliations
    Quality of Life in Oncology National Platform, Besançon, France

    Methodological and Quality of Life in Oncology Unit (INSERM UMR 1098), University Bourgogne Franche-Comté, University Hospital, Besançon, France
    Search for articles by this author
  • Virginie Nerich
    Correspondence
    Address for correspondence: Virginie Nerich, PharmD, PhD, Department of Pharmacy University Hospital, Boulevard Fleming, 25030 Besancon Cedex, France. Fax: +33 370632424
    Affiliations
    Department of Pharmacy, University Hospital, Besançon, France

    INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, University Bourgogne Franche-Comté, Besançon, France
    Search for articles by this author
Published:November 07, 2018DOI:https://doi.org/10.1016/j.clgc.2018.10.016

      Abstract

      Background

      Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse. The purpose of this retrospective study was to evaluate cost of illness for 224 patients with mccRCC included in the cohort published by Thiery-Vuillemin et al (Factors influencing overall survival for patients with metastatic clear-cell renal cell-carcinoma in daily practice. Clin Genitourin Cancer 2018; 16:e297-305), and then to determine the explanatory factors of cost of illness.

      Patients and Methods

      The study was performed from the French Public Healthcare System perspective with lifetime horizon. Only direct medical costs were included. Multiple linear regression was used to search for explanatory factors of cost of illness. The robustness of results was assessed.

      Results

      The mean cost of illness was estimated at €71,185 ± 52,683. Outpatient/inpatient treatment and hospitalization represented 76.0% and 19.7% of this cost, respectively. After adjustment, 5 explanatory factors were identified: time of disease control for the metastatic first-line treatment ≥6 months, number of lines of treatment >2, nephrectomy at metastatic stage, lack of metastases at presentation, and age at metastatic diagnosis younger than 65 years. Individually, they increased cost of illness by 128%, 95%, 53%, 53%, and 23%, respectively.

      Conclusion

      Although it is difficult to transpose our economic evaluation results to those obtained in other countries, it should be noted that our findings were consistent with them and robust. To our knowledge, our study was the first to accurately identify explanatory factors of cost of illness. Identifying them could enable us to predict the budgetary effect on a regional level of managing patients who began their first-line treatment with a targeted therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferlay J.
        • Steliarova-Foucher E.
        • Lortet-Tieulent J.
        • et al.
        Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.
        Eur J Cancer. 2013; 49: 1374-1403
      1. American Cancer Society. Kidney Cancer. Available at: https://www.cancer.org/cancer/kidney-cancer.html; https://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_2017_web.pdf. Accessed October, 2018.

        • Escudier B.
        • Pluzanska A.
        • Koralewski P.
        • et al.
        Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
        Lancet. 2007; 370: 2103-2111
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125-134
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab vs. everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Choueiri T.K.
        • Escudier B.
        • Powles T.
        • et al.
        Cabozantinib vs. everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1814-1823
        • Rini B.I.
        • Escudier B.
        • Tomczak P.
        • et al.
        Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
        Lancet. 2011; 378: 1931-1939
        • Sternberg C.N.
        • Davis I.D.
        • Mardiak J.
        • et al.
        Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
        J Clin Oncol. 2010; 28: 1061-1068
        • Hudes G.
        • Carducci M.
        • Tomczak P.
        • et al.
        Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
        N Engl J Med. 2007; 356: 2271-2281
        • Motzer R.J.
        • Escudier B.
        • Oudard S.
        • et al.
        Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
        Lancet. 2008; 372: 449-456
        • Nerich V.
        • Hugues M.
        • Paillard M.J.
        • et al.
        Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma.
        Onco Targets Ther. 2014; 7: 365-374
        • Ko J.J.
        • Xie W.
        • Kroeger N.
        • et al.
        The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
        Lancet Oncol. 2015; 16: 293-300
        • Soerensen A.V.
        • Donskov F.
        • Hermann G.G.
        • et al.
        Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.
        Eur J Cancer. 2014; 50: 553-562
        • Pal S.K.
        • Nelson R.A.
        • Vogelzang N.
        Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
        PLoS One. 2013; 8: e63341
        • Shek D.
        • Tomlinson B.
        • Brown M.
        • Brunson A.
        • Pan C.X.
        • Lara P.N.
        Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
        Clin Genitourin Cancer. 2012; 10: 93-98
        • Ljungberg B.
        • Albiges L.
        • Bensalah K.
        • Bex A.
        • Giles R.H.
        • et al.
        • European Association of Urology
        Renal cell carcinoma.
        (Available at:) (Accessed October, 2018)
        • Shih Y.C.
        • Chien C.R.
        • Xu Y.
        • Pan I.W.
        • Smith G.L.
        • Buchholz T.A.
        Economic burden of renal cell carcinoma: part I--an updated review.
        Pharmacoeconomics. 2011; 29: 315-329
        • Lang K.
        • Danchenko N.
        • Gondek K.
        • Schwartz B.
        • Thompson D.
        The burden of illness associated with renal cell carcinoma in the United States.
        Urol Oncol. 2007; 25: 368-375
        • Mantovani L.G.
        • Morsanutto A.
        • Tosolini F.
        • et al.
        The burden of renal cell cancer: a retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database.
        Eur J Cancer Suppl. 2008; 6: 46-51
        • Geynisman D.M.
        • Hu J.C.
        • Liu L.
        • Tina Shih Y.C.
        Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
        Clin Genitourin Cancer. 2015; 13: e93-e100
        • Gupta K.
        • Miller J.D.
        • Li J.Z.
        • Russell M.W.
        • Charbonneau C.
        Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
        Cancer Treat Rev. 2008; 34: 193-205
        • Maroun R.
        • Maunoury F.
        • Benjamin L.
        • Nachbaur G.
        • Durand-Zaleski I.
        In-hospital economic burden of metastatic renal cell carcinoma in France in the era of targeted therapies: analysis of the French National Hospital Database from 2008 to 2013.
        PLoS One. 2016; 11: e0162864
        • Maroun R.
        • Fleury L.
        • Nachbaur G.
        • Maunoury F.
        • Vanhille J.
        • Durand-Zaleski I.
        Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
        Curr Med Res Opin. 2017; 33: 1755-1762
        • De Groot S.
        • Blommestein H.M.
        • Redekop W.K.
        • et al.
        Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: a real-world cost-effectiveness analysis of sequential first- and second-line treatments.
        PLoS One. 2017; 12: e0177364
        • Nazha S.
        • Prevost N.
        • Tanguay S.
        • Vanhuyse M.
        Economic evaluation of targeted therapies in metastatic clear renal cell carcinoma in Canada.
        Value Health. 2016; 9: A727
        • Choueiri T.K.
        • McDermott D.
        • Sheng Duh M.
        • Sarda S.P.
        • Neary M.P.
        • Oh W.K.
        Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
        Urol Oncol. 2012; 30: 848-855
        • Thiery-Vuillemin A.
        • Cholley T.
        • Calcagno F.
        • et al.
        Factors influencing overall survival for patients with metastatic clear-cell renal cell-carcinoma in daily practice.
        Clin Genitourin Cancer. 2018; 16: e297-e305
        • Institut National du Cancer
        Les thérapies ciblées dans le traitement du cancer en 2015 - État des lieux et enjeux.
        (Available at:) (Accessed November 22, 2018)
        • Ministère des Solidarités et de la Santé
        Les dépenses de santé en 2015 - Résultats des comptes de la santé.
        (Available at:) (Accessed November 22, 2018)
        • Greenberg D.
        • Earle C.
        • Fang C.H.
        • Eldar-Lissai A.
        • Neumann P.J.
        When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.
        J Natl Cancer Inst. 2010; 102: 82-88
        • Frederix G.W.
        • Severens J.L.
        • Hövels A.M.
        • Raaijmakers J.A.
        • Schellens J.H.
        The cloudy crystal ball of cost-effectiveness studies.
        Value Health. 2013; 16: 1100-1102
        • Haute Autorité de Santé
        Department of Economics and Public Health Assessment. Choices in Methods for Economic Evaluation.
        (Available at:) (Accessed October, 2018)
        • Yvonne M.M.
        • Bishop Y.M.
        • Fienberg S.E.
        • Holland P.W.
        Discrete Multivariate Analysis Theory and Practice.
        Springer New York, New York, NY2007
        • Flanigan R.C.
        • Salmon S.E.
        • Blumenstein B.A.
        • et al.
        Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
        N Engl J Med. 2001; 345: 1655-1659
        • Mickisch G.H.
        • Garin A.
        • van Poppel H.
        • de Prijck L.
        • Sylvester R.
        • European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group
        Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
        Lancet. 2001; 358: 966-970
        • Achermann C.
        • Stenner F.
        • Rothschild S.I.
        Treatment, outcome and prognostic factors in renal cell carcinoma - a single center study (2000-2010).
        J Cancer. 2016; 7: 921-927
        • Choueiri T.K.
        • Xie W.
        • Kollmannsberger C.
        • et al.
        The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
        J Urol. 2011; 185: 60-66
        • Flanigan R.C.
        • Mickisch G.
        • Sylvester R.
        • Tangen C.
        • Van Poppel H.
        • Crawford E.D.
        Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
        J Urol. 2004; 171: 1071-1076